found that the number of triggering receptors expressed on myeloid cell (TREM)-2+ TAMs is increased in post-transarterial chemoembolization (TACE) HCC, causing increased Gal-1 secretion to mediate the overexpression of PD-L1 in vessel endothelial cells, which turns out to compromise both the number and function of CD8+ T cells and suppress the therapeutic efficacy of anti-PD-L1 blockade (69). This evidence concerns the gene CD8A and hepatocellular carcinoma.